FCN-411

FCN-411 is a novel, proprietary, and highly potent pan-HER inhibitor developed by Fochon Pharmaceuticals for the treatment of metastatic non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). It inhibits the kinase activity of members of the epidermal growth factor receptor (EGFR) tyrosine kinase family, specifically EGFR (HER1/ErbB1), HER2 (ErbB2), and HER4 (ErbB4), thereby blocking downstream signaling pathways that drive tumor growth. FCN-411 demonstrates strong in vitro and in vivo potency against both activating and resistance mutations in EGFR, including T790M/L858R. The drug has shown favorable pharmacokinetic properties with superior brain penetration compared to approved EGFR tyrosine kinase inhibitors. Clinical trials have indicated preliminary antitumor activity, particularly in patients with EGFR-mutated NSCLC who have progressed on prior EGFR-TKI therapy[1][2][3][6].

Other names

FCN-411FCN411FCN 411